BioAge Labs, Inc (BIOA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioAge Labs, Inc (BIOA) has a cash flow conversion efficiency ratio of -0.051x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.26 Million) by net assets ($374.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BIOA market cap for the company's overall valuation and market capitalisation.
BioAge Labs, Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how BioAge Labs, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioAge Labs, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioAge Labs, Inc ranked by their cash flow conversion efficiency. Explore BIOA cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Waterstone Financial Inc
NASDAQ:WSBF
|
0.027x |
|
Anhui Xinbo Aluminum Co Ltd
SHE:003038
|
-0.149x |
|
Open Lending Corp
NASDAQ:LPRO
|
-0.010x |
|
RDC Semiconductor Co Ltd
TWO:3228
|
0.003x |
|
Zhejiang Hengwei Battery Co. Ltd.
SHE:301222
|
N/A |
|
Kairuide Holding Co Ltd
SHE:002072
|
0.006x |
|
JTL Industries Ltd
NSE:JTLIND
|
-0.053x |
|
Fine Semitech Corp
KQ:036810
|
-0.021x |
Annual Cash Flow Conversion Efficiency for BioAge Labs, Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of BioAge Labs, Inc from 2013 to 2025. View today's stock price for BioAge Labs, Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $272.05 Million | $-81.63 Million | -0.300x | -88.18% |
| 2024-12-31 | $323.13 Million | $-51.52 Million | -0.159x | -174.00% |
| 2023-12-31 | $-173.40 Million | $-37.36 Million | 0.215x | -32.97% |
| 2022-12-31 | $-112.56 Million | $-36.18 Million | 0.321x | +123.58% |
| 2017-12-31 | $21.85 Million | $-29.79 Million | -1.363x | -75.73% |
| 2016-12-31 | $48.49 Million | $-37.62 Million | -0.776x | -11.68% |
| 2015-12-31 | $46.36 Million | $-32.20 Million | -0.695x | -77.97% |
| 2014-12-31 | $57.53 Million | $-22.45 Million | -0.390x | +7.82% |
| 2013-12-31 | $65.01 Million | $-27.52 Million | -0.423x | -- |
About BioAge Labs, Inc
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhib… Read more